Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hunter

Showing results (641-650 of 654) with videos related to

Pageof 66
Sort By:
Bioorganic & Medicinal Chemistry|October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase BIan Collins, John Caldwell, Tatiana Fonseca, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2025
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic AstrocytomaJessica L Fleming, Stephanie L Pugh, Susan M Chang, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
Bone Research|January 19, 2026
Thrombospondin 1 and 2 regulate mesenchymal progenitor cell fate and matrix organizationMadysen K Hunter, Sneha Korlakunta, Neda Vishlaghi, et al.
Biotechnology Progress|August 20, 2019
Factors affecting sedimentational separation of bacteria from bloodWilliam G Pitt, Mahsa Alizadeh, Rae Blanco, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Journal of Clinical and Translational Science|June 20, 2022
Barriers and solutions to developing and maintaining research networks during a pandemic: An example from the iELEVATE perinatal networkDonna A Santillan, Debra S Brandt, Rachel Sinkey, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
Pageof 66

Showing results (641-650 of 654) with videos related to

Sort By:
Pageof 66
Bioorganic & Medicinal Chemistry|October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase BIan Collins, John Caldwell, Tatiana Fonseca, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2025
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic AstrocytomaJessica L Fleming, Stephanie L Pugh, Susan M Chang, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
Bone Research|January 19, 2026
Thrombospondin 1 and 2 regulate mesenchymal progenitor cell fate and matrix organizationMadysen K Hunter, Sneha Korlakunta, Neda Vishlaghi, et al.
Biotechnology Progress|August 20, 2019
Factors affecting sedimentational separation of bacteria from bloodWilliam G Pitt, Mahsa Alizadeh, Rae Blanco, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Journal of Clinical and Translational Science|June 20, 2022
Barriers and solutions to developing and maintaining research networks during a pandemic: An example from the iELEVATE perinatal networkDonna A Santillan, Debra S Brandt, Rachel Sinkey, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
Pageof 66